


Figure 1

Code #	Gender	Age	Patient History	Medications	Disease	MW	Protein Name	Sequence
SJ CON 06	F	77			MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 07	M	65	GE (gastroesophageal) reflux		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 10	F	50	Inferior MI, Hiatal Hernia		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 14	F	65	MI, NIDDM		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 17	M	58			MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 19	M	52			MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 21	M	65			MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ22					MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ28					MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ33					MI	1211	Complement C3f	(H)RIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used tPA		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-30	M	56	HTN, ICH		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)		Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
23604 - KKB	M	61	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23707 - KL	F	65	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22703 - MMS	F	67	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20206 - MM	F	75	STAGE 4		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22103 - GM	F	77	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
21813 - GR	F	65	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23402 - HM	M	67	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20208 - HIF	M	79	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22803 - HB	M	60	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23616 - JGK	M	43	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23421 - FB	M	59	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22813 - CL	F	66	STAGE 4		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23105 - FC	M	64	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23116 - FC	M	59	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20414 - EYG	F	76	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23134 - FC	M	62	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20102 - EAB	M	70	STAGE 3		CHF	1211	Complement C3f	(H)RIHWESASLL(R)



FIGURE 2A



Complement C3f - 1211 Da
(H)RIHWESASLL[R]


100% relative intensity

100% relative intensity

100% relative intensity



FIGURE 2B



2003-05-30
JPO
PATENT & TRADEMARK OFFICE



MI

NHS

